InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,427.13
(
0.00%
)
US TECH 100
18,471.60
(
-0.34%
)
Dow Jones
39,853.87
(
0.00%
)
Brent Oil
79.79
(
-1.18%
)
Bitcoin
64,235.45
(
-1.74%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

gpo344

Send PM Follow Ignore
Followers 1
Posts 225
Boards Moderated 0
Alias Born 06/13/2010

gpo344

Re: None

Wednesday, 03/13/2013 5:14:16 PM

Wednesday, March 13, 2013 5:14:16 PM

Post# of 80490
Prescription update from Rachel McMinn:

ARIA: Market leader Gleevec continues to slide
The overall CML market declined 2% in Feb, which compares to 9% growth in 2012. The decline was lead by Gleevec (-9% yr/yr), offset by 14-15% growth from Tasigna and Sprycel, and the introduction of Bosulif and Iclusig. Iclusig TRx are tracking in line with our expectations at 193 in Feb, which is ~2x of PFE’s Bosulif TRx in the second month of its launch.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up